Stapokibart, a novel monoclonal antibody targeting the IL-4Rα subunit: promising results in a retrospective cohort of patients with bullous pemphigoid.

Name: Stapokibart, a novel monoclonal antibody targeting the IL-4Rα subunit: promising results in a retrospective cohort of patients with bullous pemphigoid.
Creator: 树芬 王
Published: 2026-06-18T10:38:19.670Z
Keywords: Dermatology, Dermatological Disease

王, 树芬; Nong, Zhuoxue; Wei, Dandan; Yang, Bingning; Huang, Yulin; Zhang, Xinyu; Su, Jiaguang; Zheng, Wenjun; Wen, Sijian

doi:10.17632/5p9xbr337y.1

Stapokibart, a novel monoclonal antibody targeting the IL-4Rα subunit: promising results in a retrospective cohort of patients with bullous pemphigoid.

Published: 18 June 2026| Version 1 | DOI: 10.17632/5p9xbr337y.1

Contributors:

,

Description

This retrospective case series study collected and analyzed clinical data from patients with bullous pemphigoid (BP) who received Stapokibart treatment at our hospital, with a total of 10 patients enrolled. Treatment efficacy was evaluated by comparing changes in skin lesions, the Bullous Pemphigoid Disease Area Index (BPDAI) score, and serum immunoglobulin E (IgE) levels before and after treatment, while safety was assessed through long-term follow-up.

Files

Steps to reproduce

This study work was supported by grants from the Health Commission of Guangxi Zhuang Autonomous Region(Z-A20240542).

Institutions

First Affiliated Hospital of GuangXi Medical University
Guangxi, Nanning

Stapokibart, a novel monoclonal antibody targeting the IL-4Rα subunit: promising results in a retrospective cohort of patients with bullous pemphigoid.

Description

Files

Steps to reproduce

Institutions

Categories

Licence